



Sale of Myoconda and share placement

- **Sale of Myoconda brings significant cash injection into Giaconda.**
- **Subscription of 17.6 million ordinary shares raises further cash for Giaconda.**

Sydney, NSW, 18 February, 2010 – Giaconda Limited (ASX: GIA), today announced that it has signed an Asset Purchase Agreement to sell the Myoconda Intellectual Property for the treatment of Crohn's Disease to Australian Medical Therapy Investments Pty Limited (AMTI). Giaconda will receive an upfront payment of \$1,500,000 plus 5% of the net sales earned by AMTI from a commercialised treatment.

Under the terms of the agreement, AMTI will assume all costs for the development of the therapy through to regulatory approval and will be responsible for the commercialisation of the approved product. Commercialisation territories include Australia, New Zealand, North America and Europe.

Giaconda's Chief Executive Officer and acting Chairman, Mr Patrick McLean, stated, "We are truly pleased that we have concluded the discussions with AMTI and look forward to the expertise that the AMTI team brings to the development of Myoconda. After everything we have accomplished on Myoconda, it is comforting to know that the final development of this important therapy will be in good hands."

AMTI has also subscribed to seventeen point six million (17,600,000) ordinary shares at \$0.03 per share as part of the twenty million (20,000,000) shares approved at Giaconda's Annual General Meeting of 23 November 2009 for \$528,000. Mr McLean stated, "These are important steps in Giaconda's history and will also allow us to push forward on our other therapies more effectively and with more security."

AMTI's Managing Director, Colin Goldrick, stated, "We are excited about the prospect of bringing this ground-breaking therapy to market. Crohn's is a debilitating disease and we see great scope for significantly increasing the quality of life of many people through this therapy. Giaconda is however more than Myoconda and we believe it has a bright future with its other therapies, a future we will now share through what we see as a strategic investment in that company."

A further market update will be provided following completion of the Myoconda sale.

ENDS

About Giaconda Limited

Giaconda Limited is a biotechnology company involved in developing and licensing innovative and cost effective medical therapies in the field of gastroenterology. Giaconda's products are targeted towards the treatment of serious conditions that are not adequately addressed by any existing therapy. In this way, Giaconda's products are intended to satisfy these significant unmet medical needs of the gastrointestinal market. The Giaconda portfolio consists of four products, all of which are novel combinations of known compounds. In particular, Giaconda has Heliconda[®], a lead product for the treatment of resistant *Helicobacter pylori* infection.

GIACONDA LIMITED

Ground Floor, 44 East Street, Five Dock NSW 2046 Phone: [612] 9370 0069 Fax: [612] 9712 1469
email: info@giacondalimited.com ABN 68 108 088 517 www.giacondalimited.com

About AMTI

AMTI is a private investment and commercialisation company focusing primarily on the commercialisation of life sciences technology in major global markets.

CONTACTS:

Giaconda	AMTI
Patrick McLean Chief Executive Officer	Colin Goldrick Managing Director
T: +61 (0)2 9370 0069 O/S: +1 514 937 5440	T: +61 2 8246 6218
Mclean278@hotmail.com	colin.goldrick@amti.com.au

GIACONDA LIMITED

Ground Floor, 44 East Street, Five Dock NSW 2046 Phone: [612] 9370 0069 Fax: [612] 9712 1469
email: info@giacondalimited.com ABN 68 108 088 517 www.giacondalimited.com